Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.

Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, Zahlten-Kumeli A, Sersch MA, Li J, Huang M, Lee JH.

Int J Hematol. 2019 Aug 6. doi: 10.1007/s12185-019-02704-z. [Epub ahead of print]

PMID:
31388932
2.

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.

Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J; KEYNOTE-185 Investigators.

Lancet Haematol. 2019 Sep;6(9):e448-e458. doi: 10.1016/S2352-3026(19)30109-7. Epub 2019 Jul 18.

PMID:
31327689
3.

Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.

Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, Shimizu K.

Ann Hematol. 2019 Jul;98(7):1703-1711. doi: 10.1007/s00277-019-03702-1. Epub 2019 May 2.

PMID:
31049648
4.

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J.

N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.

PMID:
30403938
5.

Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion.

Sekiguchi N, Nomoto J, Nagata A, Kiyota M, Fukuda I, Yamada K, Takezako N, Kobayashi Y.

Biomed Res Int. 2018 Oct 4;2018:6728128. doi: 10.1155/2018/6728128. eCollection 2018.

6.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

7.

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.

Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K.

Hematol Oncol. 2018 Dec;36(5):792-800. doi: 10.1002/hon.2559. Epub 2018 Sep 19.

PMID:
30176173
8.

Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent.

Sekiguchi N, Hamano A, Kitagawa T, Kurihara Y, Ito K, Kurimoto M, Watanabe K, Hirano K, Noto S, Yamada K, Takezako N.

Blood Res. 2018 Jun;53(2):117-122. doi: 10.5045/br.2018.53.2.117. Epub 2018 Jun 25.

9.

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.

Suzuki K, Dimopoulos MA, Takezako N, Okamoto S, Shinagawa A, Matsumoto M, Kosugi H, Yoon SS, Huang SY, Qin X, Qi M, Iida S.

Blood Cancer J. 2018 May 1;8(4):41. doi: 10.1038/s41408-018-0071-x.

10.

Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.

Najima Y, Yoshida C, Iriyama N, Fujisawa S, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.

Leuk Res. 2018 Mar;66:66-72. doi: 10.1016/j.leukres.2018.01.010. Epub 2018 Feb 3.

PMID:
29407585
11.

A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation.

Takamatsu H, Wee RK, Zaimoku Y, Murata R, Zheng J, Moorhead M, Carlton VEH, Kong KA, Takezako N, Ito S, Miyamoto T, Yokoyama K, Matsue K, Sato T, Kurokawa T, Yagi H, Terasaki Y, Ohata K, Matsumoto M, Yoshida T, Faham M, Nakao S.

Br J Haematol. 2018 Nov;183(4):664-668. doi: 10.1111/bjh.15002. Epub 2017 Dec 22. No abstract available.

PMID:
29270982
12.

Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.

Iida S, Ichinohe T, Shinagawa A, Suzuki K, Takezako N, Aoki M.

Int J Hematol. 2018 Apr;107(4):460-467. doi: 10.1007/s12185-017-2390-2. Epub 2017 Dec 19.

PMID:
29260507
13.

[Lenalidomide and low-dose dexamethasone therapy for Japanese patients with newly diagnosed multiple myeloma: updated results of the MM-025 study].

Ando K, Chou T, Suzuki K, Shinagawa A, Uchida T, Taniwaki M, Hirata H, Ishizawa K, Matsue K, Okamoto S, Otsuka M, Matsumoto M, Iida S, Matsumura I, Ikeda T, Takezako N, Ogaki Y, Midorikawa S, Houck V, Ervin-Haynes A, Terui Y.

Rinsho Ketsueki. 2017;58(11):2219-2226. doi: 10.11406/rinketsu.58.2219. Japanese.

PMID:
29212972
14.

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.

Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K; Kanto CML and Shimousa Hematology Study Groups.

Cancer Sci. 2018 Jan;109(1):182-192. doi: 10.1111/cas.13430. Epub 2017 Nov 29.

15.

Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.

Takamatsu H, Takezako N, Zheng J, Moorhead M, Carlton VEH, Kong KA, Murata R, Ito S, Miyamoto T, Yokoyama K, Matsue K, Sato T, Kurokawa T, Yagi H, Terasaki Y, Ohata K, Matsumoto M, Yoshida T, Faham M, Nakao S.

Ann Oncol. 2017 Oct 1;28(10):2503-2510. doi: 10.1093/annonc/mdx340.

16.

Effects of high-intensity pulse irradiation with linear polarized near-infrared rays and stretching on muscle tone in patients with cerebrovascular disease: a randomized controlled trial.

Takeuchi N, Takezako N, Shimonishi Y, Usuda S.

J Phys Ther Sci. 2017 Aug;29(8):1449-1453. doi: 10.1589/jpts.29.1449. Epub 2017 Aug 10.

17.

Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.

Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.

Int J Clin Oncol. 2017 Oct;22(5):972-979. doi: 10.1007/s10147-017-1141-y. Epub 2017 May 26.

18.

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.

Suzuki K, Ri M, Chou T, Sugiura I, Takezako N, Sunami K, Ishida T, Izumi T, Ozaki S, Shumiya Y, Ota K, Iida S.

Cancer Sci. 2017 Mar;108(3):461-468. doi: 10.1111/cas.13166.

19.

Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.

Hagihara M, Iriyama N, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.

Oncol Rep. 2016 Nov;36(5):2976-2982. doi: 10.3892/or.2016.5110. Epub 2016 Sep 20.

PMID:
27665844
20.

Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study.

Suzuki K, Shinagawa A, Uchida T, Taniwaki M, Hirata H, Ishizawa K, Matsue K, Ogawa Y, Shimizu T, Otsuka M, Matsumoto M, Iida S, Terui Y, Matsumura I, Ikeda T, Takezako N, Ogaki Y, Midorikawa S, Houck V, Ervin-Haynes A, Chou T.

Cancer Sci. 2016 May;107(5):653-8. doi: 10.1111/cas.12916. Epub 2016 Mar 30.

21.

Gamma Heavy Chain Disease with T-cell Large Granular Lymphocytic Leukemia: A Case Report and Review of the Literature.

Iijima M, Sekiguchi N, Nagata A, Wagatsuma M, Midorikawa K, Kurimoto M, Noto S, Yamada K, Takezako N.

Intern Med. 2016;55(4):399-403. doi: 10.2169/internalmedicine.55.5042. Epub 2016 Feb 15. Review.

22.

Effect of high-intensity pulse irradiation with linear polarized near-infrared rays on muscle tone in patients with cerebrovascular disease: a randomized controlled trial.

Takeuchi N, Takezako N, Shimonishi Y, Usuda S.

J Phys Ther Sci. 2015 Dec;27(12):3817-23. doi: 10.1589/jpts.27.3817. Epub 2015 Dec 28.

23.

[Achievement of deep molecular response in an elderly chronic myeloid leukemia patient intolerant to imatinib and nilotinib].

Kurimoto M, Nagata A, Sekiguchi N, Noto S, Takezako N.

Rinsho Ketsueki. 2015 Dec;56(12):2467-71. doi: 10.11406/rinketsu.56.2467. Japanese.

PMID:
26725357
24.

Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.

Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Konishi J, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, Shimizu K.

Blood Cancer J. 2015 Sep 18;5:e349. doi: 10.1038/bcj.2015.79. No abstract available.

25.

Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.

Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.

Am J Hematol. 2015 Sep;90(9):819-24. doi: 10.1002/ajh.24096.

26.

Recombinant human thrombomodulin in the treatment of acute myeloid leukemia patients complicated by disseminated intravascular coagulation: retrospective analysis of outcomes between patients treated with heparin and recombinant human thrombomodulin therapy.

Takezako N, Sekiguchi N, Nagata A, Homma C, Takezako Y, Noto S, Natori K, Miwa A.

Thromb Res. 2015 Jul;136(1):20-3. doi: 10.1016/j.thromres.2015.03.029. Epub 2015 Apr 10.

PMID:
25934464
27.

Significance of lymphocyte counts at diagnosis in the management of ITP: the relationship between lymphocyte counts and treatment success in H. pylori-infected patients.

Nagata A, Sekiguchi N, Kurimoto M, Noto S, Takezako N.

Int J Hematol. 2015 Mar;101(3):268-72. doi: 10.1007/s12185-015-1737-9. Epub 2015 Jan 28.

PMID:
25628102
28.

Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.

Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.

Am J Hematol. 2015 Apr;90(4):282-7. doi: 10.1002/ajh.23923. Epub 2015 Mar 2.

29.

Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.

Sekiguchi N, Ootsubo K, Wagatsuma M, Midorikawa K, Nagata A, Noto S, Yamada K, Takezako N.

Int J Hematol. 2014 Mar;99(3):288-95. doi: 10.1007/s12185-014-1514-1. Epub 2014 Feb 5.

PMID:
24496825
30.

Bortezomib, dexamethasone, and high-dose melphalan as conditioning for stem cell transplantation in young Japanese multiple myeloma patients: a pilot study.

Takezako N, Sekiguchi N, Nagata A, Homma C, Noto S, Miwa A.

Indian J Hematol Blood Transfus. 2013 Sep;29(3):147-51. doi: 10.1007/s12288-012-0177-4. Epub 2012 Jul 29.

31.

Extramedullary hematopoietic pleural effusion accompanied by follicular lymphoma.

Sekiguchi N, Noto S, Wagatsuma M, Midorikawa K, Tezuka S, Hagino T, Saito I, Yamada K, Takezako N, Miwa A.

Intern Med. 2013;52(24):2801-4.

32.

YM-175 induces apoptosis of human native monocyte-lineage cells via inhibition of prenylation.

Miwa A, Takezako N, Hayakawa H, Hayakawa M, Tominaga S, Yanagisawa K.

Am J Hematol. 2012 Dec;87(12):1084-8. doi: 10.1002/ajh.23328. Epub 2012 Oct 9.

33.

Soluble ST2 protein inhibits LPS stimulation on monocyte-derived dendritic cells.

Nagata A, Takezako N, Tamemoto H, Ohto-Ozaki H, Ohta S, Tominaga S, Yanagisawa K.

Cell Mol Immunol. 2012 Sep;9(5):399-409. doi: 10.1038/cmi.2012.29. Epub 2012 Aug 27.

34.

Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapy.

Sekiguchi N, Takezako N, Nagata A, Wagatsuma M, Noto S, Yamada K, Miwa A.

Intern Med. 2011;50(21):2653-7. Epub 2011 Nov 1.

35.

Ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide therapy for central nervous system recurrence of diffuse large B-cell lymphoma in patients with poor performance status: a pilot study.

Miwa A, Sekiguchi N, Tanimura A, Homma C, Shikai T, Takezako Y, Yamagata N, Takezako N.

Leuk Lymphoma. 2011 Oct;52(10):1898-903. doi: 10.3109/10428194.2011.588759. Epub 2011 Jun 8.

PMID:
21649542
36.

[Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl].

Sekiguchi N, Takezako N, Haga M, Nagata A, Noto S, Miwa A.

Rinsho Ketsueki. 2011 Feb;52(2):87-9. Japanese.

PMID:
21403430
37.

ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells.

Aoki S, Hayakawa M, Ozaki H, Takezako N, Obata H, Ibaraki N, Tsuru T, Tominaga S, Yanagisawa K.

Mol Cell Biochem. 2010 Feb;335(1-2):75-81. doi: 10.1007/s11010-009-0244-9. Epub 2009 Sep 12.

PMID:
19756962
38.

Marked hepatomegaly due to AA type amyloidosis in a case with Castleman's disease.

Yamagata N, Fujio J, Hirai R, Matsumaru M, Tanimura S, Inokuchi C, Shikai T, Takezako N, Nasu M, Sakata Y, Sata N, Nagai H, Saito K, Miwa A.

Int J Hematol. 2006 Jul;84(1):70-3.

PMID:
16867906
39.

ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells.

Takezako N, Hayakawa M, Hayakawa H, Aoki S, Yanagisawa K, Endo H, Tominaga S.

Biochem Biophys Res Commun. 2006 Mar 10;341(2):425-32. Epub 2006 Jan 11.

PMID:
16426569
40.

T-helper type 2 cell-specific expression of the ST2 gene is regulated by transcription factor GATA-3.

Hayakawa M, Yanagisawa K, Aoki S, Hayakawa H, Takezako N, Tominaga S.

Biochim Biophys Acta. 2005 Apr 5;1728(1-2):53-64.

PMID:
15733533
41.

Intensified conditioning regimen has only limited value for patients with progressive multiple myeloma.

Takezako N, Miwa A, Tanimura A, Inokuchi C, Shikai T, Yamagata N, Togawa A.

Int J Hematol. 2003 Oct;78(3):270-1. No abstract available.

PMID:
14604290
42.

[Myelodysplastic syndrome accompanied by Evans syndrome].

Takezako N, Shikai T, Tanimura A, Inokuchi C, Yamagata N, Masaki N, Miwa A.

Rinsho Ketsueki. 2003 Jun;44(6):396-400. Review. Japanese.

PMID:
12884819
43.

Fungal Infection in Neutropenic Patients in a Hospital during Construction.

Yonemori K, Takezako N, Nishimura K, Onose T, Yamanishi F, Kawahata H, Kawana A, Mori N, Kirikae F, Saruta K, Kirikae T, Kuratsuji T, Kudo K, Kobori O, Yazaki Y, Miwa T.

Jpn J Infect Dis. 2002 Aug;55(4):126-7. No abstract available.

PMID:
12403910
44.

Prognostic factors in elderly patients with acute myelogenous leukemia: a single center study in Japan.

Nannya Y, Kanda Y, Oshima K, Kaneko M, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Matsuyama T, Takezako N, Miwa A, Togawa A.

Leuk Lymphoma. 2002 Jan;43(1):83-7.

PMID:
11908740
45.

The diagnostic value of kappa/lambda ratios determined by flow cytometric analysis of biopsy specimens in B-cell lymphoma.

Chizuka A, Kanda Y, Nannya Y, Oshima K, Kaneko M, Yamamoto R, Suguro M, Hamaki T, Matsuyama T, Takezako N, Miwa A, Togawa A.

Clin Lab Haematol. 2002 Feb;24(1):33-6.

PMID:
11843896
46.

Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.

Kaneko M, Kanda Y, Oshima K, Nannya Y, Suguro M, Yamamoto R, Chizuka A, Hamaki T, Matsuyama T, Takezako N, Miwa A, Togawa A.

Ann Hematol. 2002 Jan;81(1):33-6. Epub 2001 Nov 10.

PMID:
11807633
47.

Lack of correlation between clinical characteristics and serum soluble Fas ligand levels in patients with multiple myeloma.

Kanda Y, Ara C, Chizuka A, Yamamoto R, Hamaki T, Suguro M, Matsuyama T, Takezako N, Miwa A, Tohma J, Shirakawa K, Yatomi T, Nakamura N, Hirai H, Togawa A.

Leuk Lymphoma. 2001 Jan;40(3-4):351-6.

PMID:
11426557
48.

Clinical value of serial measurement of serum C-reactive protein level in neutropenic patients.

Yonemori K, Kanda Y, Yamamoto R, Hamaki T, Suguro M, Chizuka A, Matsuyama T, Takezako N, Miwa A, Togawa A.

Leuk Lymphoma. 2001 May;41(5-6):607-14.

PMID:
11378578
49.

Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma.

Oshima K, Kanda Y, Nannya Y, Kaneko M, Hamaki T, Suguro M, Yamamoto R, Chizuka A, Matsuyama T, Takezako N, Miwa A, Togawa A, Niino H, Nasu M, Saito K, Morita T.

Am J Hematol. 2001 May;67(1):1-5.

50.

Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure.

Yamamoto R, Kanda Y, Matsuyama T, Oshima K, Nannya Y, Suguro M, Chizuka A, Hamaki T, Takezako N, Miwa A, Kami M, Mori S, Kojima T, Saito K, Itaoka Y, Kashida M.

Bone Marrow Transplant. 2000 Sep;26(6):685-8.

Supplemental Content

Loading ...
Support Center